## **Group sequential clinical trials**

```
# Design a Pocock group sequential clinical trial with
# five equal groups, distance 2.9 between the null and
# alternative parameters, standard deviation 4.8,
# significance level 0.05, and power 0.9.
> library(clinfun)
> gsdesign.normal ( ifrac=(1:5)/5, delta=2.9, sd=4.8,
                    sig.level=0.05, power=0.9, delta.eb=0)
 Group sequential design for comparing normal data with delta = 2.9 , sd = 4.8
   power family of boundary; 0 (Pocock) to 0.5 (O'Brien-Fleming)
  sample size (per arm) = 69.52065
   information fraction = 0.2 0.4 0.6 0.8 1.0
      efficacy boundary = 2.414 2.414 2.414 2.414 (power = 0)
               sig.level = 0.05
                  power = 0.9
             alternative = two.sided
# Here ifrac = information fraction (0.2, 0.4, ..., 1.0),
# delta.eb = boundary for efficacy, it = 0 means Pocock boundaries
# (delta.fb = boundary for futility, = 0.5 means O'Brien-Fleming)
# As a result, we sample ceiling(69.6/5) = 14 patients for each group.
# The trial will stop and reject Ho as soon as |Z(k)| > 2.417.
# Design an O'Brien-Fleming test for the same problem.
> gsdesign.normal(ifrac=(1:5)/5, delta=2.9, sd=4.8,
                    sig.level=0.05, power=0.9, delta.eb=0.5)
 Group sequential design for comparing normal data with delta = 2.9 , sd = 4.8
   power family of boundary; 0 (Pocock) to 0.5 (O'Brien-Fleming)
  sample size (per arm) = 59.13287
   information fraction = 0.2 0.4 0.6 0.8 1.0
      efficacy boundary = 4.564 3.227 2.635 2.282 2.041 (power = 0.5)
               sig.level = 0.05
                  power = 0.9
             alternative = two.sided
> # For the O'Brien-Fleming test, we sample ceiling (59.1/5) = 12 patients
> # for each group. The trial will stop
># - after the 1st group if |Z(1)| > 4.56, otherwise,
> # - after the 2nd group if |Z(2)| > 3.224, otherwise,
> # - after the 3rd group if |Z(3)| > 2.633, otherwise,
> # - after the 4th group if |Z(4)| > 2.28, otherwise,
> # - after the 5th group if |Z(5)| > 2.039.
```